Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Assets Average (2016 - 2025)

Vanda Pharmaceuticals' Assets Average history spans 14 years, with the latest figure at $545.0 million for Q4 2025.

  • For Q4 2025, Assets Average fell 16.23% year-over-year to $545.0 million; the TTM value through Dec 2025 reached $545.0 million, down 16.23%, while the annual FY2025 figure was $572.6 million, 12.22% down from the prior year.
  • Assets Average for Q4 2025 was $545.0 million at Vanda Pharmaceuticals, down from $612.9 million in the prior quarter.
  • Across five years, Assets Average topped out at $652.0 million in Q2 2024 and bottomed at $538.3 million in Q1 2021.
  • The 5-year median for Assets Average is $628.2 million (2022), against an average of $615.2 million.
  • The largest annual shift saw Assets Average rose 12.21% in 2021 before it dropped 16.23% in 2025.
  • A 5-year view of Assets Average shows it stood at $586.8 million in 2021, then grew by 7.03% to $628.0 million in 2022, then rose by 2.71% to $645.0 million in 2023, then rose by 0.87% to $650.7 million in 2024, then dropped by 16.23% to $545.0 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Assets Average are $545.0 million (Q4 2025), $612.9 million (Q3 2025), and $628.3 million (Q2 2025).